TST786

TST786 is a next generation trispecific antibody candidate targeting PD1-VEGF and GREMLIN-1, and GREMLIN-1 is a stromal fibroblast regulatory protein and contributes to metastatsis and has been negatively associated with overall survival. Currently PD1-VEGF bispecifics have shown promising PFS benefits but OS benefit is to be confirmed. Our trispecific ab has the potential not only improve PFS benefits but also have high chance to improve OS benefits by blocking tumor metastasis. It is at pre-clinical stage.